Psilocybin opioid study pulled before it began
NCT ID NCT06005662
First seen Feb 28, 2026 · Last updated Apr 30, 2026 · Updated 3 times
Summary
This study aimed to see if adding a single high dose of psilocybin (30 mg) to standard buprenorphine treatment could help people with opioid use disorder stay off illicit opioids and improve their quality of life. It was designed for adults aged 21-70 who were not already on opioid medications. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Johns Hopkins University
Baltimore, Maryland, 21224, United States
Conditions
Explore the condition pages connected to this study.